Sanofi-aventis acquires Merck's interest in Merial Ltd.
Whitehouse Station, N.J. -- Global pharmaceutical company Sanofi-aventis is now sole owner of Merial Ltd. after purchasing Merck & Co.?s remaining 50 percent interest for $4 billion.
Whitehouse Station, N.J.
-- Global pharmaceutical company Sanofi-aventis is now sole owner of Merial Ltd. after purchasing Merck & Co.'s remaining 50 percent interest for $4 billion.
Richard Clark, Sanofi-aventis president and CEO, said the deal allows the ongoing merger between Merck and Intervet/Schering-Plough Animal Health to stay on track.
If Merck and Shering-Plough merge, Sanofi-aventis has the option to combine Merial with the newly merged company under a joint venture. Such a deal would still be subject to approval by international antitrust authorities.
Newsletter
From exam room tips to practice management insights, get trusted veterinary news delivered straight to your inbox—subscribe to dvm360.
FDA approves oral drug for broad canine protection against parasites
October 7th 2024Elanco's lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets (Credelio Quattro) provide a single monthly dose for protection against fleas, ticks, heartworms, roundworms, hookworms, and 3 species of tapeworm.
Read More
dvm360 announces winners of the Veterinary Heroes program
Published: September 6th 2024 | Updated: November 5th 2024This year’s event is supported by corporate sponsor Schwarzman Animal Medical Center and category sponsors Blue Buffalo Natural, MedVet, Banfield Pet Hospital, Thrive Pet Healthcare and PRN Pharmacal.
Read More
